Section Arrow
SVRA.NASDAQ
- Savara
Quotes are at least 15-min delayed:2026/07/22 08:16 EDT
Pre Market
Last
 5.831
-0.009 (-0.15%)
Bid
5.83
Ask
6.07
High 6.04 
Low 5.831 
Volume
Regular Hours (Closed)
Last
 5.84
+0.35 (+6.38%)
Day High 
6.025 
Prev. Close
5.49 
1-M High
6.475 
Volume 
2.86M 
Bid
5.83
Ask
6.07
Day Low
5.47 
Open
5.51 
1-M Low
5.395 
Market Cap 
1.13B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 5.87 
20-SMA 5.93 
50-SMA 5.47 
52-W High 7.005 
52-W Low 2.43 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.56/-0.15
Enterprise Value
1.15B
Balance Sheet
Book Value Per Share
0.86
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JUNSJupiter Neurosciences Inc0.1697+0.0047+2.85%-- 
Pre Market 0.1334 -0.0363 -21.39%
VIVSVivoSim Lab Inc0.45-0.0549-10.87%0.47PE
Pre Market 0.4584 +0.0084 +1.87%
IOVAIovance Biotherapeutics5.48+0.46+9.16%-- 
Pre Market 5.498 +0.018 +0.33%
GOSSGossamer Bio0.1548+0.0138+9.79%-- 
Pre Market 0.1519 -0.0029 -1.87%
RXRXRecursion Pharmaceuticals3.08+0.19+6.57%-- 
Pre Market 3.0099 -0.0701 -2.28%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.